Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Weighted Average and Diluted) (2016 - 2025)

Amphastar Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 13 years, most recently at $0.51 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $0.51 for Q4 2025, down 31.08% from a year ago — trailing twelve months through Dec 2025 was $2.03 (down 33.66% YoY), and the annual figure for FY2025 was $2.03, down 33.66%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.51 at Amphastar Pharmaceuticals, up from $0.37 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AMPH hit a ceiling of $0.91 in Q3 2023 and a floor of $0.1 in Q1 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.51 (2025), compared with a mean of $0.53.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 637.5% in 2021 and later crashed 52.56% in 2025.
  • Amphastar Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.4 in 2021, then skyrocketed by 62.5% to $0.65 in 2022, then increased by 6.15% to $0.69 in 2023, then grew by 7.25% to $0.74 in 2024, then crashed by 31.08% to $0.51 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.51 (Q4 2025), $0.37 (Q3 2025), and $0.64 (Q2 2025) per Business Quant data.